ABSTRACT
It was established that the administration of an aqueous solution of bis(µ-tartrato)di(µ-hydroxy) germanate (IV) triethanolammonium to animals daily for 2 months at a dose of the active substance of 10 mg/kg of the animal's weight leads to inhibition of the total activity of the alkaline phospholipase A2 of mononuclear cells. The results of the study can be used to correct lipid metabolism in the development of disorders in hyperlipidemia. This makes it possible to expand the scope of use of the studied substance and create new pharmaceuticals based on bis(µ-tartrato)di(µ-hydroxy) germanate (IV) triethanolammonium prevent and inhibit the development of hyperlipidemia.
Subject(s)
Ethanolamines/pharmacology , Hyperlipidemias/drug therapy , Organometallic Compounds/pharmacology , Phospholipase A2 Inhibitors/pharmacology , Phospholipases A2/metabolism , Animals , Cholesterol/blood , Germanium/chemistry , Germanium/pharmacology , Hyperlipidemias/enzymology , Hyperlipidemias/pathology , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/enzymology , Lipid Metabolism/drug effects , Lipids/blood , Phospholipases A2/blood , RabbitsABSTRACT
The molecular imprinted polymers (MIPs) for penicillins and tetracyclines described in the literature were analysed with a purpose of evaluating their possible use for the antibiotic sorption isolation.
Subject(s)
Anti-Bacterial Agents/isolation & purification , Molecular Imprinting , Penicillins/isolation & purification , Polymers/chemical synthesis , Tetracyclines/isolation & purification , Methacrylates/chemistry , Molecular Structure , Polymers/chemistry , Solid Phase MicroextractionABSTRACT
Molecular imprinted polymers (MIP) for macrolides, aminoglycosides and some other biosynthetic antibiotics described in the literature were analysed with a purpose of evaluating their possible use for the antibiotics sorption.
Subject(s)
Anti-Bacterial Agents/isolation & purification , Molecular Imprinting/methods , Polymers/chemistry , Aminoglycosides/chemistry , Aminoglycosides/isolation & purification , Anti-Bacterial Agents/chemistry , Macrolides/chemistry , Macrolides/isolation & purification , Polymers/chemical synthesis , Protein Synthesis Inhibitors/chemistry , Protein Synthesis Inhibitors/isolation & purificationABSTRACT
For the past four years a joint research and development effort designed to develop steady state, intense ion sources has been in progress with the ultimate goal to develop ion sources and techniques that meet the two energy extreme range needs of meV and hundreads of eV ion implanters. This endeavor has already resulted in record steady state output currents of high charge state of antimony and phosphorus ions: P(2+) [8.6 pmA (particle milliampere)], P(3+) (1.9 pmA), and P(4+) (0.12 pmA) and 16.2, 7.6, 3.3, and 2.2 pmA of Sb(3+)Sb(4+), Sb(5+), and Sb(6+) respectively. For low energy ion implantation, our efforts involve molecular ions and a novel plasmaless/gasless deceleration method. To date, 1 emA (electrical milliampere) of positive decaborane ions was extracted at 10 keV and smaller currents of negative decaborane ions were also extracted. Additionally, boron current fraction of over 70% was extracted from a Bernas-Calutron ion source, which represents a factor of 3.5 improvement over currently employed ion sources.
